Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1393&sort=-start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1394&sort=-start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-start_date" }, "data": [ { "type": "Grant", "id": "5950", "attributes": { "award_id": "3P51OD011107-60S2", "title": "California National Primate Research Center Development of a Nonhuman Primate Model of Long COVID", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 20378, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-05-01", "end_date": "2023-04-30", "award_amount": 498994, "principal_investigator": { "id": 20379, "first_name": "Prasant", "last_name": "Mohapatra", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 746, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Revised Title: California National Primate Research Center Development of a Nonhuman Primate Model of Long COVID Revised Abstract: SARS-CoV-2, the virus that causes coronavirus disease 19 (COVID-19), is an acute respiratory infection which resolves in more than 90% of infected individuals. However, a second protracted phase of disease with multiorgan involvement has been reported. Regardless of age or infection severity, nearly one-third of recovered individuals report a constellation of symptoms often characterized by persistent fatigue and brain fog. Referred to as “Long COVID” or the “COVID-19 long-hauler syndrome” and clinically as Post-Acute Sequelae of SARSCoV-2 infection, symptoms involve the lungs, heart, vasculature, and the central nervous system. The underlying mechanisms are unknown, but immune activation/dysregulation coupled with SARS-CoV-2 viral remnants may play a role in chronic inflammation resulting in injury to otherwise healthy cells, tissues, and organs. The overall goal of this application is to determine if the SARS-CoV-2 infected rhesus macaque can develop persistent pathophysiology that recapitulates Long COVID in humans. The rationale for the proposed study is based upon reports of patients who develop chronic symptoms regardless of acute SARS-CoV-2 infection severity and a limited understanding of the biological basis for this prolonged disease state. There is therefore an urgent need to understand Long COVID and develop an animal model of infectious disease that can be used to investigate therapeutic strategies for this syndrome. Our secondary objective is to delineate the kinetics of virus shedding in the respiratory and gastrointestinal tract to facilitate long-term studies in the rhesus model outside restricted BSL3 facilities. Revised Specific Aims: Studies in the COVID-19 rhesus macaque model are critically needed to complement clinical data since the immunopathology within the lung, heart, and brain can be rigorously assessed by longitudinal functional testing and tissue analysis. We hypothesize that adult rhesus macaques will develop chronic inflammation and functional deficits associated with the cardiopulmonary, immune and nervous systems following recovery from acute SARS-CoV-2 infection. To test this hypothesis, we will inoculate a cohort of aged male rhesus macaques with SARS-CoV-2 and progressively monitor animals for viral shedding. Assessment of cardiovascular and lung function will be conducted following confirmation of viral nucleic acid clearance using highly sensitive assays. To delineate how virological and immunological responses following SARS-CoV-2 impact parameters of cardiovascular fitness and lung function to direct the clinical manifestations of Long COVID, we will complete the following Specific Aims: Aim 1: Establish spatiotemporal kinetics of viral nucleic acid persistence and immune activation in the upper and lower respiratory tract, and gastrointestinal tract following SARS-CoV-2 infection. We will conduct serial sampling for SARS-CoV-2 in nasal passages, distal lung, and rectum to quantify the degree of viral shedding over time using validated RT-PCR methods as well as a novel CRISPR based assay. Immune profiling will be conducted in blood and lung lavage. Aim 2: Assess the impact of SARS-CoV-2 infection on cardiovascular and pulmonary function. We will assess animals for cardiovascular measures (echocardiogram, doppler) and lung function (static lung mechanics) at baseline and following viral nucleic acid clearance at 10- and 24-weeks post-infection with SARSCoV-2. Aim 3: Determine the impact of vaccination following SARS-CoV-2 infection on immune, cardiovascular and pulmonary function. Following viral nucleic acid clearance, we will vaccinate and monitor immune activation/dysregulation, cardiovascular and lung function at 10-weeks post-infection with SARS-CoV-2.", "keywords": [ "Address", "Age", "Alzheimer&apos", "s Disease", "Anatomy", "Appointment", "Area", "Behavior", "Biological Assay", "Biomedical Research", "California", "Caring", "Clinical Pathology", "Collaborations", "Communicable Diseases", "Communities", "Core Facility", "Development", "Disease", "Ensure", "Flow Cytometry", "Fostering", "Funding", "Funding Agency", "Genetic", "Goals", "Grant", "Growth", "Health", "Health Services", "Human", "Information Technology", "Infrastructure", "Inhalation Exposure", "Institution", "Investigation", "Knowledge", "Laboratories", "Lead", "Longevity", "Lung diseases", "Medical", "Medicine", "Mentors", "Mission", "Modeling", "Multimodal Imaging", "National Institute on Aging", "Neurosciences", "Pilot Projects", "Prevention", "Primates", "Quality of life", "Regenerative Medicine", "Rejuvenation", "Reproductive Sciences", "Research", "Research Design", "Research Personnel", "Research Priority", "Research Support", "Research Training", "Resources", "Role", "Schools", "Science", "Scientist", "Services", "Site", "Training", "Translations", "United States National Institutes of Health", "Universities", "Veterinarians", "Vision", "ZIKA", "animal care", "animal facility", "base", "behavioral health", "career", "college", "design", "fighting", "high standard", "human disease", "improved", "industry partner", "next generation", "nonhuman primate", "operation", "outreach", "population health", "pre-clinical", "programs", "psychologic", "public-private partnership", "recruit", "responsible research conduct", "success", "supportive environment", "tool", "translational impact", "translational scientist" ], "approved": true } }, { "type": "Grant", "id": "7373", "attributes": { "award_id": "3P30CA030199-39S1", "title": "Cancer Center Support Grant (CCSG)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 20549, "first_name": "Sonya", "last_name": "Roberson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-05-01", "end_date": "2025-04-30", "award_amount": 487500, "principal_investigator": { "id": 23166, "first_name": "GARTH", "last_name": "POWIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1428, "ror": "https://ror.org/03m1g2s55", "name": "Sanford Burnham Prebys Medical Discovery Institute", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1428, "ror": "https://ror.org/03m1g2s55", "name": "Sanford Burnham Prebys Medical Discovery Institute", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The scientific community has mobilized around the novel coronavirus, SARS-CoV-2 which causes the pneumonia like disease named COVID-19. This virus has impacted over 210 countries and territories and almost 1.5 million people worldwide since December 2019, according to the Coronavirus Disease (COVID19) Situation Dashboard by the World Health Organization. The current research efforts across the globe center on understanding the disease, and importantly developing therapeutics and vaccines. There are currently no FDA approved drugs or vaccines for CoVs, yet three clinical stage or approved compounds have shown some promise: Remdesivir (Gilead), Favipiravir (Fujifilm), and Hydroxychloroquine (off patent). However, finding additional agents that can be used in a cocktail therapy, that may potentiate the activities of these clinical stage compounds, mitigate any potential adverse effects by allowing for lower dosing, and diminish chances of resistance development, will be an important therapeutic strategy for antiviral treatment. Thus, the identification of effective antivirals that synergize with these compounds to limit SARS-CoV-2 replication and disease represents an urgent public health necessity. We have recently completed a screen of the novel ReFRAME (Repurposing, Focused Rescue, and Accelerated MedChem) drug repositioning collection, to identify inhibitors of SARS-CoV-2 replication, and have validated over 30 clinical stage molecules that may function as SARS-CoV2 antivirals (manuscript in preparation). While these compounds function as single agents, due to the many advantages provided by combination therapy, including the potential to overcome suboptimal efficacy of individual drugs, we now propose to execute three screens in the presence of IC20 concentrations of Remdesivir, Favipiravir, or Hydroxychloroquine to identify known drugs that synergize with each of these advanced clinical candidates. Following validation of screen hits, we will then test drugs combinations with an additional clinical stage compounds (Remdesivir, Favipiravir, or Hydroxychloroquine) to identify 3 drug cocktails displaying maximal synergistic activity. By leveraging the prior investments in medicinal chemistry, pharmacology, and toxicology of the ReFRAME library, drug cocktails inhibiting SARS-CoV-2 infection will be able to be moved quickly into clinical trials to address this immediate public health emergency.", "keywords": [ "2019-nCoV", "Address", "Adverse effects", "Antiviral Agents", "Applications Grants", "Area", "Basic Science", "Biomedical Research", "Biotechnology", "COVID-19", "Cancer Center", "Cancer Center Support Grant", "Cancer Patient", "Cancer Science", "Cessation of life", "Clinical", "Clinical Trials", "Collaborations", "Collection", "Combined Modality Therapy", "Communities", "Country", "County", "Diagnosis", "Disease", "Dose", "Drug Combinations", "FDA approved", "Gene Targeting", "Graduate Degree", "Grant", "Human", "Hydroxychloroquine", "Individual", "Infection", "Institutes", "International", "Investments", "Laboratories", "Libraries", "Malignant Neoplasms", "Manuscripts", "Medical Research", "Mission", "Modality", "Names", "Organizational Change", "Pharmaceutical Chemistry", "Pharmaceutical Preparations", "Pharmacology and Toxicology", "Pneumonia", "Preparation", "Prevention", "Private Sector", "Public Health", "Research", "Research Institute", "Research Personnel", "Resistance development", "Scientist", "Therapeutic", "Training", "Translating", "Translations", "Vaccines", "Validation", "Virus", "Vision", "World Health Organization", "anticancer research", "base", "cancer therapy", "clinical candidate", "coronavirus disease", "dashboard", "drug discovery", "drug testing", "inhibitor/antagonist", "multidisciplinary", "next generation", "novel", "novel coronavirus", "novel therapeutics", "off-patent", "pre-clinical", "preclinical development", "public health emergency", "recruit", "remdesivir", "small molecule", "therapeutic development", "working group" ], "approved": true } }, { "type": "Grant", "id": "6006", "attributes": { "award_id": "3P42ES007380-23S1", "title": "UK NIEHS SRP Project # 3 Supplement Relating to Extending Halo-organic Capture/Remediation Technology to Corona Virus Membrane Mask and Enclosed Space Air Filter Development", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 20526, "first_name": "Heather F.", "last_name": "Henry", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-04-07", "end_date": "2025-01-31", "award_amount": 277361, "principal_investigator": { "id": 20527, "first_name": "Kelly G", "last_name": "Pennell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: Through our NIEHS-SRP research we have advanced materials (membranes to adsorptive and recognition-based polymers) development for degradation and capture/sensing of toxic organics from water. Membranes and polymers-based technologies are also used in air filtration area to remove particles and aerosols. Learning from nanoparticles and virus to organic separations from water media, we propose to advance the aqueous treatment technology and science to create advanced mask and enclosed space air filtration platform to capture coronavirus particles in a transformative way. By expanding on our current specific aims, the overall goal will be to bring interaction-based capture and recognition with highly efficient airborne coronavirus removal with easy breathability and air filtration properties. The transfer of smart materials development knowledge from water remediation area to airborne virus removal area will bring in immense benefit to society and human health. Virus nanoparticles (micro aerosols) build-up in enclosed air space is critical factor in viral transmission. For the enclosed space air filter, unique regenerative mechanisms will be developed. This supplement will allow us to add virus capture/deactivation functionality so that our on-going halo-organic capture/destruction technology will also be effective against coronavirus (COVID-19) environmental pollutant. Our work will involve pseudotype virus particles, and we will also concentrate on the outer surface S-protein and functionalized, synthetic nanoparticles.", "keywords": [ "2019-nCoV", "Address", "Adhesives", "Adsorption", "Aerosols", "Affinity", "Air", "Anti-Bacterial Agents", "Appearance", "Area", "Binding", "Biochemistry", "Biomedical Research", "Breathing", "COVID-19", "Cations", "Confined Spaces", "Coronavirus", "Data Collection", "Dental crowns", "Development", "Drops", "Electrostatics", "Engineering", "Environmental Pollutants", "Excision", "Exhibits", "Exposure to", "Frequencies", "Gel", "Generations", "Glycoproteins", "Goals", "Health", "Heating", "Human", "Humidity", "Hydration status", "Hydrogels", "Hydrogen Bonding", "Immobilization", "Knowledge", "Lead", "Learning", "Literature", "Magnetism", "Masks", "Membrane", "Membrane Proteins", "Metals", "Methods", "Modification", "Molecular", "Morphology", "Mucins", "Nanostructures", "National Institute of Environmental Health Sciences", "Natural regeneration", "Nature", "Nutritional Science", "Oxides", "Permeability", "Phase", "Polymers", "Property", "Proteins", "Public Health", "Reactive Oxygen Species", "Reporting", "Research", "Risk", "Science", "Signal Recognition Particle", "Societies", "Source", "Sulfhydryl Compounds", "Surface", "Swelling", "System", "Technology", "Thick", "Variant", "Virion", "Virus", "Virus Inactivation", "Water", "Work", "aerosolized", "air filter", "air filtration", "aqueous", "base", "crosslink", "design", "food science", "graphene", "hazard", "iron oxide", "magnetic field", "materials science", "monomer", "nanocomposite", "nanoparticle", "novel", "particle", "physical property", "pollutant", "polyvinylidene fluoride", "pressure", "programs", "regenerative", "remediation", "superfund site", "symposium", "transmission process", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "7455", "attributes": { "award_id": "3P30CA046934-32S3", "title": "SARS-COV-2 Environmental Constraint Effects on Cancer Prevention and Management Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22891, "first_name": "Min", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-04-04", "end_date": "2022-01-31", "award_amount": 155500, "principal_investigator": { "id": 23248, "first_name": "RICHARD D", "last_name": "SCHULICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "The Univ. of Colorado Cancer Center (UCCC) will participate in a consortium with other NCI-designated cancer centers to conduct a cross-sectional study within their respective regional catchment area populations. The consortium is led by the Univ. of Alabama (UAB), Birmingham’s O'Neal Comprehensive Cancer Center. The first aim of the consortium is to investigate whether the SARS-COV-2 pandemic has impacted individuals’ behaviors known to be associated with the development or prevention of cancer malignancies such as tobacco use, alcohol consumption, and physical activity. We are interested in investigating whether constraints due to the pandemic such as social distancing, loss of employment, and mental health challenges have affected individuals’ health behaviors differently due to their age, race/ethnicity, rural/urban residency, or socio-economic status. UCCC will survey 1,500 individuals who experience cancer disparities in our catchment (Colorado), including individuals of Hispanic descent, who live in poverty, and reside in rural or frontier counties. We will use the Univ. of Colo. Health Survey Registry (Registry) to draw a sub-sample of individuals from these populations in Colorado. The Registry is enrolled from respondents to the statewide Tobacco Attitudes and Behavior Survey (TABS) on Health, a crosssectional population survey conducted in Colorado. The second aim of the consortium is to investigate whether constraints associated with the pandemic impacted cancer patients and survivors’ ability to receive cancer treatment, follow-up or surveillance procedures, treatment regimens as prescribed, participation clinical trials, and interventions to manage pain and treatment side-effects. We will investigate if the pandemic impacted these outcomes differently for patients based on differences in their demographic characteristics, type of cancer diagnosed and stage of diagnosis, as well as their treatment status (active treatment, posttreatment survivorship). Moreover, we are also interested in investigating whether the SARS-COV-2 pandemic negatively affected outcomes that are important to cancer patients (patient-centered outcomes) such as their social and emotional functioning, quality of life, coping, social support/connectedness, and financial hardship due to loss of employment or health insurance associated with the pandemic’s constraints. In Colorado, we will leverage our collaboration with UCCC’s Oncology Research Information Exchange Network (ORIEN)/Total Cancer Care study platform to field a survey to 1,000 cancer patients and survivors who have been previously consented at UCCC to be contacted for research purposes. Constructs measured will be examined using descriptive statistics, with focus on how specific groups differ. Geospatial information will be used to compare area-based measures (e.g., socioeconomic indicators) to individual-level measures. Multilevel modeling will be conducted to understand the relationship between demographic variables and cancer preventive and cancer management outcomes and how the relationship is moderated by the SARS-COV-2 pandemic.", "keywords": [ "2019-nCoV", "Acute Myelocytic Leukemia", "Address", "Affect", "Alabama", "Alcohol consumption", "Androgen Receptor", "Area", "Attitude", "Autophagocytosis", "Behavior", "Behavior Therapy", "Behavioral Sciences", "Cancer Biology", "Cancer Center", "Cancer Center Support Grant", "Cancer Control", "Cancer Model", "Cancer Patient", "Cancer Science", "Cancer Survivor", "Cancer Therapy Evaluation Program", "Catchment Area", "Cellular biology", "Characteristics", "Clinical", "Clinical Research", "Clinical Trials", "Collaborations", "Colorado", "Complement", "Comprehensive Cancer Center", "Computational Biology", "Consent", "Consultations", "Coordination and Collaboration", "Critiques", "Cross-Sectional Studies", "Development", "Developmental Therapeutics Program", "Diagnosis", "Diagnostic", "Disease", "Ecology", "Education", "Employment", "Enrollment", "Ensure", "Epidemiology", "Epigenetic Process", "Ethnic Origin", "Faculty", "Faculty Recruitment", "Financial Hardship", "Funding", "Future", "Gap Junctions", "Genomics", "Grant", "Guanosine Triphosphate Phosphohydrolases", "Hand", "Head Cancer", "Health", "Health Insurance", "Health Services", "Health Surveys", "Health behavior", "Healthcare Systems", "Hematologic Neoplasms", "Hispanics", "Hospitals", "Hypoxia", "Immunobiology", "Individual", "Infrastructure", "Institution", "Intervention", "Investments", "Laboratories", "Leadership", "Lung", "Malignant Neoplasms", "Malignant neoplasm of lung", "Malignant neoplasm of urinary bladder", "Measures", "Medicine", "Mental Health", "Mentorship", "Metabolic Pathway", "Mission", "Molecular Structure", "NCI-Designated Cancer Center", "NTRK1 gene", "Neck Cancer", "Network-based", "New Agents", "Noninfiltrating Intraductal Carcinoma", "Oncology", "Outcome", "PTGS2 gene", "Pain management", "Palliative Care", "Patient Care", "Patient-Focused Outcomes", "Patients", "Pediatric Hospitals", "Physical activity", "Policy Research", "Population", "Population Sciences", "Postpartum Period", "Poverty", "Pre-Clinical Model", "Prevention", "Prevention trial", "Preventive", "Primary Health Care", "Procedures", "Protocols documentation", "Quality of life", "Race", "Registries", "Research", "Research Infrastructure", "Research Personnel", "Residencies", "Resource Sharing", "Respondent", "Rural", "Sampling", "Scientist", "Secure", "Shapes", "Signal Pathway", "Social Distance", "Social Functioning" ], "approved": true } }, { "type": "Grant", "id": "5923", "attributes": { "award_id": "3P30ES007048-25S1", "title": "Environmental Exposures, Host Factors and Human Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 20235, "first_name": "Claudia L", "last_name": "Thompson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-04-01", "end_date": "2021-05-31", "award_amount": 127359, "principal_investigator": { "id": 20236, "first_name": "ROB S", "last_name": "MCCONNELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 152, "ror": "https://ror.org/03taz7m60", "name": "University of Southern California", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Emerging data indicate disproportionate COVID-19 death rates among members of racial/ethnic minority groups in the United States. The contribution of demographic factors, socioeconomic status (SES), population mobility, and environmental exposures is unclear. Using California death certificate data, we will study potential determinants of probable COVID-19 deaths and excess all-cause mortality during the pandemic. In Aim 1 we will evaluate the independent contribution of acute (prior 1-8 weeks) and chronic (prior 1-2 years) air pollution exposure to COVID-19 mortality and excess all-cause mortality that has been observed during the pandemic. In Aim 2 we will estimate the joint association of individual level demographic determinants (e.g., sex, age, race/ethnicity) and contextual factors (e.g., neighborhood demographics/SES, time-varying cell-phone based mobility, air pollution). The expected outcome of this investigation is an improved understanding of the effect of ambient air pollution on COVID-19 mortality risk and the impact of individual and contextual factors on COVID- 19 mortality, with a goal of discerning factors that may have led to the troubling higher COVID-19 mortality being observed in racial/ethnic minority populations. Study findings will have an important positive impact by identifying characteristics of high-risk, vulnerable communities that can guide more targeted and effective public health interventions. Clarifying the role of air pollution in COVID-19 deaths could be highly relevant to air quality regulations that potentially could reduce mortality.", "keywords": [ "Acute", "Air Pollution", "COVID-19", "COVID-19 mortality", "California", "Cellular Phone", "Characteristics", "Chronic", "Color", "Communities", "Data", "Death Certificates", "Death Rate", "Demographic Factors", "Environmental Exposure", "Ethnic Origin", "Exposure to", "Goals", "Individual", "Integration Host Factors", "Investigation", "Joints", "Minority Groups", "Neighborhoods", "Outcome", "Population", "Race", "Role", "Socioeconomic Status", "Time", "United States", "air quality regulation", "ambient air pollution", "base", "contextual factors", "demographics", "ethnic minority population", "high risk", "human disease", "improved", "member", "mortality", "mortality risk", "pandemic disease", "public health intervention", "racial and ethnic", "racial and ethnic disparities", "sex" ], "approved": true } }, { "type": "Grant", "id": "7629", "attributes": { "award_id": "3P30ES005022-33S1", "title": "A randomized crossover trial of portable air cleaners to reduce PM and SARS-CoV-2 exposures at home", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 11803, "first_name": "Claudia L", "last_name": "Thompson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-04-01", "end_date": "2024-03-31", "award_amount": 254770, "principal_investigator": { "id": 23428, "first_name": "HELMUT", "last_name": "ZARBL", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1418, "ror": "", "name": "RBHS-SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1418, "ror": "", "name": "RBHS-SCHOOL OF PUBLIC HEALTH", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "Americans newly infected with SARS-CoV-2 (SC2) are directed to isolate at home with care provided by household members. Isolation from others may be difficult to maintain for 2 weeks, especially in economically challenged households without enough space to create a private sick room and bathroom. The CDC recommends that at-home patients and their caregivers use makeshift facemasks for care-giver protection. They do not address the possibility of virus spread via smaller particles that are not captured by improvised facemasks. Accumulating evidence supports the significance of patient-generated aerosols, with and without ambient PM, in the transmission of SC2 infection, but haven’t been subject to controlled study. U.S. PM2.5 concentrations are linked to a 15% increase in COVID-19 deaths per ?g/m3 of PM2.5, suggesting an interaction between the two stressors. Thus, we plan to quantify SC2 in different PM fractions in home isolation rooms of newly diagnosed individuals Moreover, a common recommendation to reduce indoor aerosol exposures is filtration, and based on our experience we plan a crossover trial of air cleaners in home isolation rooms. We hypothesize that portable indoor particle filters will reduce both airborne PM and associated viral particle concentrations in the air around patients. We aim to test this hypothesis by enrolling 20 individuals from our employee health clinics with newly diagnosed SC2 infections in a cross-over randomized trial of home air cleaners. These will be continuously operated alternately for two consecutive 24-hour cycles, one cycle with a HEPA filter, and the other with a sham filter. Size selective impactors in the isolation room will elucidate particle sizes most associated with virus. Samplers will allow capture of PM2.5, PM coarse (10-2.5), and >PM10 fractions. In both the isolation room and the main living area we will collect total inhalable particles (d<100 µm) at 10 L/min. These samples will be used in initial analyses to check if there is sufficient viral RNA in individual impactor stages for reliable detection and quantification. Concentrations of PM and virus will be compared between filtered and sham conditions .The greatest impact of our studies will be finding of a significant viral concentration in the aerosol range (specifically, particles < 10 µm) documenting the potential for aerosol exposure to SC2. Finding substantial viral content in aerosol size fractions will have additional public health implications, as preventing person-to-person aerosol transmission is more challenging than preventing transmission via larger droplets, the focus of almost all current prevention recommendations.", "keywords": [ "2019-nCoV", "Address", "Aerosols", "Air", "American", "Area", "Biological Assay", "COVID-19", "Cardiopulmonary", "Caregivers", "Caring", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Characteristics", "Clinic", "Clinical Trials", "Communities", "Controlled Study", "Cross-Over Trials", "Detection", "Development", "Devices", "Employee Health", "Enrollment", "Epidemiology", "Exposure to", "Extravasation", "Filtration", "Handwashing", "Home environment", "Hospitals", "Hour", "Household", "Individual", "Infection", "Lead", "Link", "Methodology", "Methods", "Morbidity - disease rate", "Newly Diagnosed", "Particle Size", "Particulate", "Pathogenesis", "Pathogenicity", "Patients", "Performance", "Persons", "Prevention", "Privatization", "Public Health", "RNA", "Randomized", "Recommendation", "Reporting", "Respiratory Tract Infections", "Saliva", "Sampling", "Satellite Viruses", "Security", "Single-Blind Study", "Source", "Testing", "Viral", "Virus", "air cleaner", "air filter", "air sampling", "base", "coarse particles", "effectiveness measure", "experience", "experimental study", "fine particles", "health care settings", "high efficiency particulate air filter", "indoor particulate matter", "laboratory experiment", "member", "mortality", "novel", "particle", "portability", "prevent", "racial disparity", "randomized trial", "stressor", "transmission process", "ventilation", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "7486", "attributes": { "award_id": "3P30CA013148-48S2", "title": "COVID-19 and Its Implications for Cancer Prevention and Control: A Collaborative Effort Across Cancer Centers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22891, "first_name": "Min", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-03-28", "end_date": "2022-03-31", "award_amount": 371250, "principal_investigator": { "id": 23288, "first_name": "BARRY P", "last_name": "SLECKMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "The unexpected COVID-19 pandemic has the potential to trigger major behavior changes worldwide, which, consequently, may have significant implications for cancer prevention, management, and survivorship efforts, particularly among sub-populations experiencing cancer disparities. Thus, it is imperative to be prepared and adapt our ongoing and future strategies across the cancer care continuum within this new context through participatory evidence-based approaches. Given the urgency, and how rapidly these changes are occurring, we must take advantage of ongoing collaborative efforts to maximize resources and accelerate implementation of these new strategies based on the needs and wants of different sub-populations in the U.S. The overall goal of this collaborative with four other cancer centers (Iowa, Detroit, Colorado, and Ohio) is to work together to rapidly develop a standard set of core questions to incorporate into surveys that can be administered to populations across the U.S. using protocols that can be delivered by cancer center/university staff working remotely (e.g., online and telephone). Although five cancer centers are moving forward with the supplement, other cancer centers are willing to join our efforts so we have begun a coordinated effort to engage them in the process in the event additional resources become available. The specific aims are: 1. To assess how differences in demographics (rural/urban, age, gender, race, educational attainment) will impact engagement in cancer preventive behaviors (e.g., tobacco cessation) and cancer management/survivorship behaviors (e.g., adherence to treatment, adherence to surveillance) in the context of COVID-19 environmental constraints (e.g., social distancing, employment, mental health, etc.) among adult healthy volunteers, cancer patients, and cancer survivors in Alabama (field center); 2. To provide coordination of efforts and technical assistance regarding data management and analysis to all participating cancer centers (coordinating center); 3. To strengthen the collaboration with the participating cancer centers toward the development and implementation of cancer prevention & control strategies in the context of COVID-19 (coordinating center)", "keywords": [ "Address", "Adherence", "Adult", "African American", "Age", "Alabama", "Animal Model", "Area", "Arkansas", "B-Lymphocytes", "Behavior", "Behavior Therapy", "Biological Markers", "Body Weight", "Brain Neoplasms", "COVID-19", "COVID-19 pandemic", "Cancer Biology", "Cancer Center", "Cancer Control", "Cancer Patient", "Cancer Survivor", "Cancer Vaccines", "Catchment Area", "Chemopreventive Agent", "Clinic", "Clinical Trials", "Collaborations", "Colorado", "Comparative Effectiveness Research", "Comprehensive Cancer Center", "Continuity of Patient Care", "Data Analyses", "Deep South", "Detection", "Development", "Diagnosis", "Diagnostic", "Diet", "Disease", "Disease Progression", "Early Diagnosis", "Employment", "Event", "Functional Imaging", "Future", "Gender", "Gene Expression", "Genomic Instability", "Genotype", "Goals", "Health Services Accessibility", "Heart", "Human", "Human Biology", "Imaging technology", "Immunology", "Immunotherapeutic agent", "Incidence", "Industry", "Inflammation", "Interdisciplinary Study", "Intervention", "Investigation", "Iowa", "Knowledge", "Laboratories", "Link", "Louisiana", "Malignant Neoplasms", "Malignant neoplasm of brain", "Mental Health", "Mission", "Mississippi", "Molecular and Cellular Biology", "Morbidity - disease rate", "Neoplasm Metastasis", "Obesity", "Ohio", "Outcome", "Outcomes Research", "Pathogenesis", "Pathway interactions", "Patients", "Pharmacology", "Phase", "Phenotype", "Physical activity", "Population", "Predisposition", "Prevention", "Preventive", "Process", "Protocols documentation", "Public Health", "Quality of life", "Race", "Recording of previous events", "Research", "Resources", "Risk", "Rural", "Scientist", "Signal Transduction", "Social Distance", "Surveys", "Systems Biology", "T-Lymphocyte", "Telephone", "Testing", "Therapeutic", "Tobacco Use Cessation", "Tobacco use", "Translating", "Translational Research", "Translations", "Universities", "Vision", "Work", "base", "behavior change", "biomarker identification", "cancer biomarkers", "cancer care", "cancer cell", "cancer health disparity", "cancer prevention", "cancer risk", "cancer stem cell", "carcinogenesis", "cell behavior", "data management", "demographics", "dietary manipulation", "drug development", "drug discovery", "end of life", "energy balance", "evidence base", "experience", "healthy volunteer", "high risk population", "improved", "innovation", "mortality", "new therapeuti" ], "approved": true } }, { "type": "Grant", "id": "7487", "attributes": { "award_id": "3P30CA013148-48S5", "title": "COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22891, "first_name": "Min", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-03-28", "end_date": "2022-03-31", "award_amount": 100000, "principal_investigator": { "id": 23288, "first_name": "BARRY P", "last_name": "SLECKMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "OVERALL COMPONENT ABSTRACT The UAB CCC is the only NCI designated comprehensive cancer center in the states of Alabama, Mississippi, Louisiana and Arkansas, states with higher cancer mortality and significant minority, mostly African American populations. The Cancer Center is in its 44th year of NCI funding and continues its major contributions to translational therapeutics and cancer disparity research with a focus on training minority investigators. The UAB CCC has 242 members who come from 30 departments in 9 UAB schools, Southern Research, and HudsonAlpha Institute for Biotechnology. The members are supported by $92,055,777 in annual direct extramural funding. The UAB CCC is organized into six research programs, two each in basic, translational, and prevention and control – Inflammation, Immunology & Immunotherapeutics; Cancer Cell Biology; Experimental Therapeutics; Neuro-Oncology; Cancer Chemoprevention; and Cancer Control & Population Sciences. Members published 1,684 cancer focused, peer reviewed publications between 2011 and 2015 of which 24% were intra-programmatic, 16% inter-programmatic, and 53% inter-institutional. These members are supported by eleven shared facilities – Biostatistics & Bioinformatics, Comprehensive Genomics, High Resolution Imaging, Human Imaging, Mass Spectrometry/2D Proteomics, Microbiome/Gnotobiotic, Preclinical Imaging, Recruitment & Retention, Structural Biology, Tissue Procurement, and Transgenic Animals as well as the developing Pharmacometrics Shared Facility. We have established a Phase I Clinical Trials Program, opened an Advanced Imaging Facility, advanced targets through the Alabama Drug Discovery Alliance, created the UAB Health System Cancer Community Network, and are now a consortium with HudsonAlpha Institute for Biotechnology. In addition to these achievements, we have created an Institute for Cancer Outcomes and Survivorship, and established a critical mass of investigators in energy balance and cancer. We have also expanded our minority training programs that since 2005 have trained 59 scholars resulting in 306 publications, 67 grant submissions with 30 funded, and have had a major impact at Morehouse School of Medicine and Tuskegee University. We have recruited 47 investigators to multiple programs in the Cancer Center since 2010. Strategic plans developed in 2011 with crosscutting themes of Translational Therapeutics, Systems Biomedicine, and Energetics and Cancer continue to be highly relevant today. For the future, we will continue to emphasize translational and cancer disparity research with an emphasis on personalized/genomic medicine, energy balance and cancer, outcomes and survivorship, and early phase clinical trials.", "keywords": [ "Achievement", "Address", "African American", "Age", "Alabama", "Animal Model", "Area", "Arkansas", "B-Lymphocytes", "Behavior Therapy", "Bioinformatics", "Biological Markers", "Biometry", "Biotechnology", "Body Weight", "Brain Neoplasms", "Cancer Biology", "Cancer Center", "Cancer Control", "Cancer Survivor", "Cancer Vaccines", "Catchment Area", "Cellular biology", "Chemopreventive Agent", "Clinic", "Clinical Trials", "Community Networks", "Comparative Effectiveness Research", "Comprehensive Cancer Center", "Deep South", "Detection", "Development", "Diagnosis", "Diagnostic", "Diet", "Disease", "Disease Progression", "Early Diagnosis", "Extramural Activities", "Functional Imaging", "Funding", "Future", "Gene Expression", "Genomic Instability", "Genomics", "Genotype", "Gnotobiotic", "Goals", "Grant", "Health Services Accessibility", "Health system", "Heart", "Human", "Human Biology", "Imaging technology", "Immunology", "Immunotherapeutic agent", "Incidence", "Industry", "Inflammation", "Institutes", "Interdisciplinary Study", "Intervention", "Investigation", "Investigational Therapies", "Knowledge", "Laboratories", "Link", "Louisiana", "Malignant Neoplasms", "Malignant neoplasm of brain", "Mass Spectrum Analysis", "Minority", "Mission", "Mississippi", "Molecular and Cellular Biology", "Morbidity - disease rate", "Morehouse School of Medicine", "Neoplasm Metastasis", "Obesity", "Outcome", "Outcomes Research", "Pathogenesis", "Pathway interactions", "Patients", "Peer Review", "Pharmacology", "Phase", "Phase I Clinical Trials", "Phenotype", "Physical activity", "Population", "Population Sciences", "Predisposition", "Prevention", "Proteomics", "Public Health", "Publications", "Publishing", "Quality of life", "Recording of previous events", "Research", "Research Personnel", "Risk", "Schools", "Scientist", "Signal Transduction", "Strategic Planning", "System", "Systems Biology", "T-Lymphocyte", "Testing", "Therapeutic", "Tissue Procurements", "Tobacco use", "Training", "Training Programs", "Transgenic Animals", "Translating", "Translational Research", "Translations", "Universities", "Vision", "Work", "biomarker identification", "cancer biomarkers", "cancer cell", "cancer chemoprevention", "cancer health disparity", "cancer risk", "cancer stem cell", "carcinogenesis", "cell behavior", "dietary manipulation", "drug development", "drug discovery", "early phase clinical trial" ], "approved": true } }, { "type": "Grant", "id": "6267", "attributes": { "award_id": "3P01AG005842-32S2", "title": "Improving Health Outcomes for an Aging Population", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21194, "first_name": "PARTHA", "last_name": "BHATTACHARYYA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-02-01", "end_date": "2023-06-30", "award_amount": 161388, "principal_investigator": { "id": 21195, "first_name": "Katherine", "last_name": "Baicker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 739, "ror": "https://ror.org/04grmx538", "name": "National Bureau of Economic Research", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 739, "ror": "https://ror.org/04grmx538", "name": "National Bureau of Economic Research", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Drug Treatments and the Impact of COVID-19 on Alzheimer’s Patients and Other Vulnerable Populations Interventions in health policy and care management have the potential to reduce COVID-19 infections and deaths, particularly if they can be targeted to the most vulnerable populations such as patients with Alzheimer's Disease and Related Dementias (ADRD). In this supplement proposal, we compile information and develop tools that can accelerate and target such interventions. The first aim is to identify the medical and socioeconomic characteristics of people that make them most vulnerable to COVID-19. We create cohorts of patients with ADRD and for other vulnerable populations based on their Fall 2019 characteristics, and follow them through 2020 to identify those at greatest risk of both “direct” COVID-19 outcomes (e.g., critical illness, mortality) and “indirect” increases in non-COVID outcomes. The second aim is an ambitious proof of concept: using natural experiments to shed light on novel drugs to treat or prevent COVID-19 with a particular focus on drugs most heavily used by ADRD patients (e.g., anticholinesterase inhibitors). We will develop and apply a machine learning approach to test the potential effect of drug classes on COVID-19, measured by diagnosis, hospitalization, ICU admission, and death. This supplement is made possible by a unique opportunity: Access to near-real-time Medicare claims data (one-month lag), which CMS appears willing to make available through an expedited data use agreement. The application will supplement an ongoing program project on Improving Health Outcome for an Aging Population, whose overarching aim is to better understand health trends and disparities, determinants of health, and approaches to improving health for an aging population in an evolving landscape.", "keywords": [ "Address", "Administrative Supplement", "Admission activity", "Affect", "Age", "Agreement", "Alzheimer&apos", "s disease patient", "Alzheimer&apos", "s disease related dementia", "Angiotensin-Converting Enzyme Inhibitors", "Back", "Biological", "COVID-19", "COVID-19 pandemic", "Caring", "Cessation of life", "Characteristics", "Cholinesterase Inhibitors", "Chronic", "Clinical", "Code", "Collaborations", "Communities", "Contracts", "Critical Illness", "Data", "Data Scientist", "Development", "Diagnosis", "Disease", "Elderly", "Emergency Situation", "Ethnic Origin", "Formularies", "Future", "General Population", "Geography", "Health", "Health Policy", "Health trends", "Healthcare", "Hospitalization", "Hydroxychloroquine", "Infection", "Institution", "Intervention", "Light", "Location", "Low income", "Machine Learning", "Measures", "Mediating", "Medicaid eligibility", "Medical", "Medicare claim", "Memantine", "Methods", "Modernization", "Natural experiment", "Nursing Homes", "Older Population", "Outcome", "Patients", "Pharmaceutical Preparations", "Pharmacologic Substance", "Pharmacotherapy", "Physician&apos", "s Practice Patterns", "Policies", "Population", "Population Density", "Population Intervention", "Race", "Randomized", "Research", "Risk", "Socioeconomic Factors", "Testing", "Time", "Triage", "Vulnerable Populations", "Work", "adverse outcome", "aged", "aging population", "base", "cohort", "drug candidate", "falls", "geographic difference", "health disparity", "health management", "high risk", "improved", "inhibitor/antagonist", "insight", "mortality", "novel therapeutics", "parent grant", "population based", "prevent", "programs", "socioeconomics", "tool" ], "approved": true } }, { "type": "Grant", "id": "6268", "attributes": { "award_id": "3P01AG005842-32S1", "title": "Improving Health Outcomes for an Aging Population", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21196, "first_name": "PARTHA", "last_name": "BHATTACHARYYA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-02-01", "end_date": "2023-06-30", "award_amount": 447421, "principal_investigator": { "id": 21197, "first_name": "Katherine", "last_name": "Baicker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 739, "ror": "https://ror.org/04grmx538", "name": "National Bureau of Economic Research", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Supplemental Project: The Impact of the COVID-19 Pandemic and Subsequent Economic Downturn on Population Health and Mortality This project supplements an ongoing program project on “Improving Health Outcomes for an Aging Population” by analyzing the impact of the COVID-19 pandemic and its associated economic downturn on population health and mortality. As significant as the reported mortality statistics from COVID-19 have become, they do not account for undiagnosed cases of COVID-19, the health and mortality costs of deferred or foregone care for other conditions, or the secondary health effects of economic distress, job loss, and social isolation. Also absent is any understanding of how these wider health effects are influenced by policy responses, notably social distancing requirements at the local and state levels, and their associated effects on business activity. While COVID-19 is fundamentally a public health crisis, focusing exclusively on its direct health effects, without accounting for the impact on the health care system and the economy -- and in turn the economy’s impact on health, provides an incomplete understanding of the pandemic’s overall impact on health and wellbeing. The goal of this supplement is to engage a small network of economic scholars to analyze near real-time data on health and mortality, and to begin to unravel these indirect and secondary health implications of the pandemic. The supplement’s aims encompass three categories of analysis on the secondary impact of the pandemic on health and mortality: (1) other health conditions affected indirectly by the pandemic, and how both the direct and indirect health impacts vary across race, ethnicity, and socioeconomic groups; (2) the dramatic economic downturn of the pandemic and the distinct impact of economic conditions on health and mortality; and (3) the social distancing policy response of different communities and states, and its relationship to economic conditions, health and mortality at the local and state levels.", "keywords": [ "Accounting", "Affect", "Age", "Businesses", "COVID-19", "COVID-19 pandemic", "Caring", "Case Study", "Categories", "Cause of Death", "Cessation of life", "Communities", "Coronavirus", "Data", "Diagnosis", "Distress", "Economic Conditions", "Economics", "Ensure", "Ethnic Origin", "Face", "Geographic Locations", "Geography", "Goals", "Government", "Health", "Health trends", "Healthcare", "Healthcare Systems", "Incubated", "Infection", "Information Dissemination", "Investigation", "Left", "Medicare claim", "Modeling", "Modernization", "Motor Vehicles", "Occupations", "Outcome", "Personal Satisfaction", "Physiological", "Policies", "Population Analysis", "Public Health", "Race", "Records", "Reporting", "Research Personnel", "Social Distance", "Social isolation", "Socioeconomic Status", "Testing", "Time", "Unemployment", "United States", "Work", "aging population", "base", "beneficiary", "career", "coronavirus disease", "cost", "economic impact", "health disparity", "improved", "infection rate", "meetings", "mortality", "mortality statistics", "pandemic disease", "parent grant", "population health", "programs", "response", "socioeconomics", "symposium" ], "approved": true } } ], "meta": { "pagination": { "page": 1393, "pages": 1405, "count": 14046 } } }